

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 79271

Title: Germline BRC variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05226098

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Director

Reviewer's Country/Territory: Japan

Author's Country/Territory: Canada

Manuscript submission date: 2022-08-14

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-09-19 02:16

Reviewer performed review: 2022-09-19 02:50

Review time: 1 Hour

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Language quality	<input checked="" type="radio"/> Grade A: Priority publishing <input type="radio"/> Grade B: Minor language polishing <input type="radio"/> Grade C: A great deal of language polishing <input type="radio"/> Grade D: Rejection
Conclusion	<input checked="" type="radio"/> Accept (High priority) <input type="radio"/> Accept (General priority) <input type="radio"/> Minor revision <input type="radio"/> Major revision <input type="radio"/> Rejection
Re-review	<input checked="" type="radio"/> Yes <input type="radio"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SPECIFIC COMMENTS TO AUTHORS

This is a well written case series paper. It will provide useful information to the reader.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 79271

Title: Germline BRC variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05848410

Position: Peer Reviewer

Academic degree: Doctor, MMed, PhD

Professional title: Chief Doctor, Chief Physician, Dean, Doctor, Professor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: Canada

Manuscript submission date: 2022-08-14

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-09-25 15:05

Reviewer performed review: 2022-09-30 19:36

Review time: 5 Days and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

The authors provide a very interesting case diagnosed with advanced PACC with liver metastasis. After chemotherapy and PARPi, the patient achieved a much better outcome. Also, the authors provide the details of a series of PACC patients and conclude the importance of genomic testing in these patients. We believed that the genomic testing is very important to these pancreatic cancer patients because of the poor prognosis. Some minor issues: 1. the case should be described with more details. 1) the chemotherapy regimens dosage and cycle time (3weeks? 4weeks?). 2) baseline information: the body surface area of the patient, elevated transaminase, and so on at diagnosis. 3) how the CT image at the cycle 2, cycle 4, and so on if it is available. 4) how is the side effect of chemo. 5) after the treatment switched to PARPi, how is the tumor size and the side effect? 6) the patient had a very high CA199 level, a mixed pancreatic cancer with PDCA?

2. As we known, because of the high toxic effects of FFX, we may not choose this regimen for a poor PS patient and only gemcitabine may be selected. Also, the patient achieved a very good outcome after cycle 4 and cycle 6, the treatment could be switched to PARPi at this time point. How the authors think about these? Therefore, a more detailed case reports should be provided. 3. The authors listed the genomic data of a series of PACC patients. The data showed a high incidence of BRCA mutation of the patients with a personal or family history of a PDCA, ovarian cancer and breast cancer?

4. The authors provide a study approval of PDCA?